PLCB1 (Phospholipase C Beta 1) encodes phospholipase C beta 1, a critical enzyme in the phosphoinositide signaling pathway. PLCB1 hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate two important second messengers: inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). These molecules regulate calcium release from intracellular stores and activate protein kinase C (PKC), respectively, making PLCB1 essential for numerous neuronal functions including synaptic plasticity, learning, memory, and neuronal development[1].
| Property | Value |
|---|---|
| Gene Symbol | PLCB1 |
| Full Name | Phospholipase C Beta 1 |
| Chromosomal Location | 20p12.3 |
| NCBI Gene ID | 23236 |
| OMIM | 607120 |
| Ensembl ID | ENSG00000141642 |
| UniProt | Q9NQ66 |
| Protein Name | Phospholipase C beta 1 (PLC-β1) |
PLCB1 has two main splice isoforms:
| Isoform | Distribution | Function |
|---|---|---|
| PLCB1a | Neurons, widespread | Full-length, neuronal function |
| PLCB1b | Testis, some brain regions | Truncated, modified regulation |
PLCβ1 contains several distinct domains:
PLCβ1 hydrolyzes PIP2 through a two-step process:
The enzyme is activated by Gq-coupled receptors and can also be activated by Gβγ subunits[2].
PLCβ1 is crucial for both long-term potentiation (LTP) and long-term depression (LTD):
LTP:
LTD:
PLCβ1-generated IP3 binds IP3 receptors (IP3R) on the endoplasmic reticulum:
PLCB1 is activated by numerous Gq-coupled receptors:
| Receptor Family | Examples | Function |
|---|---|---|
| Muscarinic ACh | M1, M3, M5 | Learning, memory |
| Metabotropic glutamate | mGluR1, mGluR5 | Synaptic plasticity |
| Serotonin | 5-HT2A, 5-HT2C | Mood, cognition |
| Alpha-adrenergic | α1A, α1B | Stress response |
| Dopamine | D1-like (indirect) | Reward, movement |
PLC signaling regulates spine structure:
PLCB1 dysfunction is implicated in AD pathogenesis[4]:
Mechanisms:
Evidence:
PLC signaling is altered in PD[5]:
Dopamine receptor signaling:
Neuroinflammation:
PLCB1 mutations are associated with epileptic encephalopathies[6]:
PLCB1 variants contribute to neurodevelopmental disorders[7]:
PLCB1 mutations cause severe early-onset epilepsy:
| Agent | Mechanism | Status |
|---|---|---|
| U73122 | PLC inhibitor | Research use |
| U73343 | Inactive analog control | Research use |
| Mecamylamine | Nicotinic antagonist (affects PLC) | Clinical |
| Lithium | Indirect PLC modulation | FDA approved |
PLCB1 is highly expressed in:
| Cell Type | Expression | Function |
|---|---|---|
| Pyramidal neurons | High | Synaptic plasticity |
| Interneurons | High | Network regulation |
| Purkinje cells | Very high | Motor learning |
| Astrocytes | Moderate | Glial signaling |
Receptor activation → Gq protein → PLCB1 activation → PIP2 hydrolysis
↓
IP3 + DAG
↓ ↓
Ca2+ release PKC activation
↓ ↓
Gene transcription Synaptic plasticity
Yang J, et al. Phospholipase C-beta signaling in neuronal function. Adv Exp Med Biol. 2020. ↩︎
Riekenberg S, et al. PLC-beta isoforms in neuronal signaling. Cell Signal. 2009. ↩︎
Kim D, et al. Phospholipase C in synaptic plasticity. Neuropharmacology. 2017. ↩︎
Jang H, et al. Phospholipase C signaling in Alzheimer's disease. J Alzheimers Dis. 2019. ↩︎
Ross CA, et al. Phospholipase C signaling in Parkinson's disease models. Neurobiol Dis. 2018. ↩︎
Yang L, et al. PLCB1 variants in epilepsy and neurodevelopmental disorders. Brain. 2018. ↩︎
Zhou Y, et al. PLCB1 and intellectual disability. Hum Mol Genet. 2019. ↩︎
Smith KR, et al. Targeting PLC signaling in brain disorders. Pharmacol Rev. 2020. ↩︎